A potential role for 1-oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) in the regulation of malignant diseases has been widely considered. In this study, we found that in transformed astroglial cells, the expression profile of lysophospholipid receptor mRNA and the action modes of LPA and S1P on cell motility were changed: there was a change in the acquisition of the ability of LPA to stimulate cell migration and a change in the migratory response to S1P from stimulation through S1P 1 to inhibition through S1P 2 . LPA-induced cell migration was almost completely inhibited by either pertussis toxin, LPA 1 receptor antagonists including Ki16425 (3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfonyl)propanoic acid) or an inhibitor of phosphatidylinositol 3-kinase (PI3K) wortmannin. The LPA-induced action was also suppressed, although incompletely, by several specific inhibitors for intracellular signaling pathways including Rac1, Cdc42, p38 mitogen-activated protein kinase (p38MAPK) and c-Jun terminal kinase (JNK), but not extracellular signalregulated kinase. Nearly complete inhibition of migration response to LPA, however, required simultaneous inhibition of both the p38MAPK and JNK pathways. Inhibition of Rac1 suppressed JNK but not p38MAPK, while the activity of p38MAPK was abolished by a dominantnegative form of Cdc42. These findings suggest that, in glioma cells, the PI3K/Cdc42/p38MAPK and PI3K/ Rac1/JNK pathways are equally important for LPA 1 receptor-mediated migration.
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Introduction
Gliomas represent about half of all brain tumors, and among them, glioblastoma multiforme is thought to be the most malignant and common intracranial tumor (Vandenberg, 1992) . Although generally not metastatic, glioblastoma cells exhibit highly migratory and invasive behavior (Ishiuchi et al., 2002) . Owing to their infiltrative nature, many of these high-grade neoplasms involve both cerebral hemispheres by invading through the corpus callosum and therefore rarely can be totally removed surgically, which makes the prognosis extremely poor. For this reason, determining the factors and mechanisms that regulate the migratory response in order to find new strategies to control the neoplastic process is of great interest.
1-Oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid (LPA), one of the simplest natural phospholipids, is an extracellular lipid mediator that evokes hormoneand growth-factor-like responses in almost every cell type, both normal and transformed. Activating its cognate GTP-binding regulatory protein (G-protein) coupled receptors, four of which have been identified so far (LPA 1 -LPA 4 ), LPA elicits diverse cellular responses ranging from cell proliferation and survival to induction of morphological changes and motility (Mills and Moolenaar, 2003) . A potential role of LPA and its receptors in the pathogenesis of human cancer, however, is a relatively new concept. LPA was implicated in human tumorigenesis from studies showing that LPA increases the motility and invasiveness of different types of cells (Imamura et al., 1993; Stam et al., 1998) . LPA has been shown to be accumulated in ascitic fluids from patients with intraperitoneal malignancies, particularly ovarian cancer and pancreatic cancer (Xu et al., 1995; Westermann et al., 1998; Yamada et al., 2004) . A major part of extracellular LPA is now known to be produced from lysophosphatidylcholine by autotaxin/lysophospholipase D, originally identified as an autocrine motility factor for melanoma cells and implicated in tumor progression (Tokumura et al., 2002; Umezu-Goto et al., 2002) . LPA 2 is overexpressed in differentiated thyroid cancer (Schulte et al., 2001) . Furthermore, LPA acts as an autocrine growth factor, and one or more LPA receptors are expressed in the prostate cancer cells (Xie et al., 2002) . In astroglial cells as well, extracellularly added LPA induces the proliferation and migration of stimulated cells (Manning et al., 2000; Steiner et al., 2002; Malchinkhuu et al., 2003; Hama et al., 2004) . Although there are enough studies related to LPAstimulated cell migration, the details of LPA signaling in migration have not been elucidated so far.
Sphingosine-1-phosphate (S1P), one of the LPA-like lysophospholipids, has also been reported to regulate cell migration in a manner dependent on the S1P receptor subtype. Of five subtypes of S1P-specific receptors (S1P 1 -S1P 5 ), S1P 1 and S1P 3 have been shown to mediate S1P-induced migration in diverse cell types (Kon et al., 1999; Wang et al., 1999; Liu et al, 2000; Kimura et al., 2003) . In contrast, in some tumor or vascular smooth muscle cells, S1P inhibits cell migration, and this inhibitory effect of S1P occurs through the S1P 2 -mediated suppression of Rac, which has been implicated in the regulation of cell movement (Okamoto et al., 2000) . In astroglial cells, however, the role of the S1P receptor subtype in the migration response has not been elucidated.
In this study, we found that the malignant transformation of astroglial cells may lead to changes in the expression of lysophospholipid receptors, especially the augmentation of S1P 2 and LPA 1 , resulting in inhibition and activation of glioma cell migration by S1P and LPA, respectively. Furthermore, we explored the role of mitogen-activated protein (MAP) kinases in LPAstimulated migration of glioma cells. LPA stimulated the migratory response in a manner dependent on p38 MAP kinase (p38MAPK) and c-Jun terminal kinase (JNK). Both enzymes were located downstream of phosphatidylinositol 3-kinase (PI3K) and were activated in parallel. However, activation of p38MAPK occurred depending on Cdc42, while JNK was activated through Rac1. Thus, the PI3K/Cdc42/p38MAPK and PI3K/ Rac1/JNK pathways may be involved in LPA-induced migration in glioma cells.
Results

LPA and S1P effects on migration are consistent with the expression of lysophospholipid receptors in astroglial cells
Consistent with previous studies showing that LPA hardly causes migration in rat astrocytes (Manning et al., 2000) , we detected no migratory response toward LPA in rat astrocytes. On the contrary, S1P stimulated migration with nanomolar potency (Figure 1a) . In glioma cells, LPA vividly induced migration, but S1P suppressed cell migration regardless of the presence of LPA (Figures 1b-e) . These opposing effects of lysophospholipids on migration could be due to the different expressions of LPA and S1P receptors in normal and transformed cells. Rat astrocytes mainly express S1P 1 and S1P 3 and only detectable amounts of LPA 1 and LPA 3 (Figure 2 ). However, all transformed cell lines express considerable amounts of LPA 1 and S1P 2 , although we have detected undeniable amounts of S1P 1 and/or S1P 3 in C6 and 1321N1 cells and of LPA 2 in GNS-3314 cells as well as 1321N1 cells. As summarized in Table 1 , surgical specimens also showed that LPA 1 and S1P 2 receptors are expressed in the highest levels among LPA and S1P receptor subtypes, respectively, as was the case for transformed cell lines such as GNS-3314 cells and 1321N1 cells. In the case of CGNH-89, however, we detected a higher amount of LPA 2 than LPA 1 . Nevertheless, its migration might be mediated by LPA 1 as described later (Figure 4c and d) . The detection of the S1P and LPA receptor expression profile in rat astrocytes is consistent with the results of other groups . The effect of S1P on the proliferation of cultured astrocytes has been reported previously (Pebay et al., 2001; Malchinkhuu et al., 2003) . To our knowledge, this is the first report showing that S1P stimulates the migration of cultured astrocytes. S1P 1 -or S1P 2 -receptor-transfected C6 cells were used to evaluate the role of each receptor in cell migration. As shown in Figure 3a , S1P 1 -transfected cells migrated toward S1P in a dose-dependent manner, but the motility of S1P 2 -transfected cells was dose dependently inhibited by S1P. The stimulatory effect of S1P on the migration of S1P 1 -transfected cells was abolished by pertussis toxin (PTX) pretreatment, while its inhibitory Figure 2 Lysophospholipid receptors expression. Total RNAs (20 mg) were prepared from rat astrocytes (AS), C6 cells (C6), GNS-3314 cells (GNS) and 1321N1 cells (132). The RNAs were then electrophoresed to analyse the expression of mRNAs of S1P 1-3 and LPA 1-3 receptors and GAPDH as described in Materials and methods ). A ratio of less than 0.00001 (described as o0.01 in the table) is not significant by this method Figure 3 Distinct role of S1P receptors in glioma cell migration. (a) S1P receptor-transfected C6 cells were stimulated by indicated concentrations of S1P. The migration was allowed to proceed as described in Materials and methods. (b and c) Effect of siRNAs on migration. CGNH-89 cells were transfected with 50 nM siRNAs for nonsilencing (NS) or S1P 2 receptor (si-S1P 2 ), and the cells were serum starved overnight. (b) The expression level of LPA 1 and S1P 2 was measured using real-time RT-PCR. (c) The transfected cells were stimulated with 100 nM LPA, 100 nM S1P or both of LPA and S1P. The migration was allowed to proceed as described in Materials and methods
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E Malchinkhuu et al effect in S1P 2 -transfected cells was not affected (data not shown). These results suggest that S1P receptors utilize distinct, subtype-specific mechanisms to regulate the cell motility. To confirm the involvement of S1P 2 receptors in the inhibition of migration, we performed experiments with siRNAs specific for S1P 2 (Figure 3b and c).
The expression of S1P 2 mRNA, but not of LPA 1 , in CGNH-89 cells was reduced by a prior treatment of cells with S1P 2 siRNAs ( Figure 3b ). And the treatment led to a marked recovery of migration previously suppressed by S1P (Figure 3c ). These results suggest that PTX-insensitive G-protein-coupled S1P 2 receptors may participate in the inhibition of cell migration.
Summarizing the results, we can hypothesize that a malignant transformation of astroglial cells leads to a change in the expression of lysophospholipid receptors from S1P 1 dominant to S1P 2 and LPA 1 dominant. A change in the profile of receptor expression may lead to a change in the action modes of two lipid mediators on cell motility.
LPA-induced migration in glioma cells is mediated by the PTX-sensitive LPA 1 receptor, but not by transactivation of the epidermal growth factor (EGF) receptor
In C6 cells as well as CGNH-89 cells, Ki16425 (3-(4-[4-([1-(2-chlorophenyl) ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfonyl)propanoic acid), an LPA receptor antagonist, specifically abolished the LPAinduced motility (Figure 4a ). Response to LPA, but not to platelet-derived growth factor (PDGF), was inhibited by PTX (Figure 4e ), suggesting an involvement of the PTX-sensitive G-protein-coupled LPA receptor in the LPA action. To unveil the LPA receptor subtypes responsible for migration, we compared the effects of several LPA receptor antagonists in rat and human glioma cells (Figure 4b ). Ki16425 has a preference for LPA 1 and LPA 3 over LPA 2 (Ohta et al., 2003) ; similarly, VPC12249 also prefers LPA 1 and LPA 3 but not LPA 2 (Heise et al., 2001) , whereas dioctylglycerol pyrophosphate (DGPP 8:0) shows a preference for only LPA 3 (Fischer et al., 2001 ). VPC12249 and Ki16425, but DGPP 8:0 significantly suppressed the LPA response. However, Ki16425 (up to 10 mM), VPC12249 or DGPP 8:0 (up to 30 mM) hardly affected PDGF-induced migration, suggesting the specificity of antagonists (data not shown). To get further convincing, we employed siRNAs for LPA 1 receptor in CGNH-89 cells (Figure 4c and d). The siRNA transfection resulted in nearly 50% reduction of LPA 1 expression without significant change in S1P 2 expression ( Figure 4c ). The reduction was accompanied by a remarkable inhibition of LPA-, but not PDGF-induced migration ( Figure 4d ). Thus, LPA 1 -specific siRNA inhibited LPA-induced migratory response. Taken together, these studies support the critical role of the PTX-sensitive G-protein-coupled LPA 1 receptor in glioma cell migration.
LPA-mediated transactivation of the EGF receptor has served as a prototype to exert G i -protein signaling pathways that lead to the activation of Ras and extracellular signal-regulated kinase (ERK) (Daub et al., 1997; Cunnick et al., 1998) . It has also been reported that LPA transactivates the EGF receptor to promote migration in some cancer cells (Gschwind et al., 2002; Schafer et al., 2004) . To test the involvement of EGF receptor in LPA-induced migration, we performed migration experiments using AG1478, a specific EGF receptor tyrosine kinase inhibitor. In Figure 4f , EGF (up to 30 ng/ml) did not cause the migration in C6 cells, and AG1478 had no effect on LPA-induced migration. In CGNH-89 cells, however, EGF evoked the migratory response to the extent similar to LPA, and this response was inhibited by AG1478. In contrast, the LPA-induced migration was not affected. Thus, we could rule out the involvement of EGF receptor transactivation in LPA-induced migration.
PI3K-, Rac1-, Cdc42-, p38MAPK-and JNK-dependent pathways are important for LPA signaling in glioma cell migration
To clarify the mechanisms involved in LPA action, we examined the effects of specific inhibitors for different kinases on cell migration. We obtained the following results (Figure 5a ): wortmannin, a specific inhibitor for PI3K, and SB203580, a p38MAPK inhibitor, significantly decreased the migration of C6 cells caused by LPA. However, neither PD98059, an inhibitor for ERK kinase (MEK), nor Y27632, a Rho-associated kinase (ROCK) inhibitor, affected cell migration. Similar results were obtained in GNS-3314 cells (Figure 5b ). In addition, the migration of GNS-3314 cells was inhibited by SP600125, an inhibitor for not only JNK but also MKK4; Ki value of JNK is 10 times lower than that of MKK4 (Bennett et al., 2001) , but the inhibition was incomplete (Figure 5c ). The same was true for the p38MAPK inhibitor SB203580. And with both inhibitors, the migration was almost completely abolished. To further evaluate the role of Rac1, Cdc42, p38MAPK and JNK in cell migration, we employed adenovirus containing dominant-negative mutants for Rac1 (T17NRac1), Cdc42 (T17Cdc42) and p38MAPK (dominant-negative mutant for p38MAPK (p38-DN)) or JNK-binding domain of JNK-interacting protein-1 (JIP1-JBD). Infection of GNS-3314 cells with the p38MAPK mutant led to the inhibition of migration to an extent similar to that caused by SB203580 (Figure 5d ). Treatment of GNS-3314 cells with T17Cdc42 mutant attenuated the migratory response to LPA (Figure 5e ). When we added SB203580 to cells infected with T17NRac1 (Figure 5f ), the number of migrating cells diminished to a level close to the basal value. The response to LPA, but not to PDGF, was attenuated in cells overexpressing JIP1-JBD (Figure 5g ). Consistent with previous results (Matsumoto et al., 1999) , we could not detect the activation of JNK by PDGF (Figure 7b ), which would explain the negative effect of JIP1-JBD overexpression upon PDGF-stimulated cell migration. (data not shown). The effect of adenovirus carrying T17NRac1 (Figure 6c ) or JIP1-JBD (data not shown) on p38MAPK activation was marginal. On the other hand, the p38MAPK activation by LPA was almost completely suppressed by dominant-negative mutant for Cdc42 (T17NCdc42) (Figure 6d ), suggesting that Cdc42 could mediate p38MAPK activation. Infection of dominant-negative mutants of p38MAPK abolished its endogenous activity (Figure 6e ) but did not influence phosphorylation of ERK1/2 (Figure 6f ). These results suggest that PI3K/Cdc42, but not Rac1, is upstream of p38MAPK activation stimulated by LPA.
LPA activates JNK through PI3K-and Rac1-dependent pathways Figure 5c and g show that the inhibition of migration by SP600125 or JIP1-JBD overexpression was incomplete. Treatment of the cells with SP600125 completely abolished the LPA-induced phosphorylation of JNK but hardly affected the phosphorylation of ERK (Figure 7a ). This result suggests that SP600125 inhibited phosphorylation possibly by MKK4, upstream enzyme of JNK, and hence inhibited JNK activity. We further examined the ability of LPA and other growth factors to phosphorylate the JNK proteins. As shown in Figure 7b , only LPA could phosphorylate the JNK proteins in contrast to S1P and PDGF, both of which were unable to activate the JNK isoforms. LPAstimulated phosphorylation of JNK was PTX sensitive (Figure 7c ) and completely inhibited by wortmannin but not by SB203580 (Figure 7d ). Dominant-negative Rac1-infected cells showed no activation of JNK in response to LPA (Figure 7e ). Taken together, these results suggest that LPA stimulated JNK through LPA 1 -mediated and PI3K/Rac1-dependent mechanisms.
PI3K-, p38MAPK-and JNK-dependent pathways are essentially required for LPA-induced Matrigel invasion of glioma cells
The possibility of LPA to stimulate the glioma cell invasion was studied using a Matrigel invasion assay. As shown in Figure 8 , LPA stimulated the invasion in GNS-3314, but S1P suppressed the invasion regardless of the presence of LPA, and the LPA action was markedly inhibited by Ki16425 treatment of the cells. Similar results were obtained with C6 cells (data not shown). Thus, LPA 1 is also an important component for the invasive activity of LPA. To assess whether the mechanisms involved in LPA-induced cell invasion are similar to that in cell migration, we examined the effects of inhibitors on cell invasion as described in Figure 5 . We obtained the following results, shown in Figure 8c : wortmannin and SP600125 almost completely decreased the invasion of GNS-3314 cells caused by LPA, while SB203580 was less effective than the inhibitors of PI3K and JNK.
Discussion
Experimental results related to LPA-induced glioma cell migration are summarized in Figure 9 . LPA, utilizing the G i -protein-coupled LPA 1 receptor, stimulates the migration of glioma cells in a PI3K/Cdc42/p38MAPK-and PI3K/Rac1/JNK-dependent manner. Based on our findings, we can conclude that p38MAPK and JNK are equally important for sufficient LPA action on glioma cell motility. Data from a variety of laboratories have indicated that several signal transduction molecules participate in the regulation of migration. The small molecular weight G-proteins, that is, Rho, Rac and Cdc42, regulate the Figure 6 LPA activates p38MAPK in PI3K-and Cdc42-dependent, but Rac1-independent manner. (a) GNS-3314 cells were stimulated with 100 nM LPA or 30 ng/ml PDGF for 10 min at 371C and cell lysates were prepared as described in Materials and methods. (b) GNS-3314 cells were pretreated with 100 nM wortmannin for 15 min. (c-e) GNS-3314 cells were infected with adenovirus containing (c) T17NRac1, (d) T17NCdc42 or (e) p38-DN, and then stimulated with 1 mM LPA. Cell lysates were subjected to measurement of p38MAPK activity. (f) Cell lysates from (e) were also subjected to Western blot analysis for detection of total p38MAPK and phosphorylated ERK (p-p44 and p-p42) Regulation of glioma migration by lysophospholipids E Malchinkhuu et al formation of the focal adhesions, lamellipodia and filipodia, respectively (Nobes and Hall, 1999) . These Rho-like G-proteins are known principally for their pivotal role in regulating the actin cytoskeleton in cell migration (Burridge and Wennerberg, 2004) . PI3K has been thought to be a key molecule in the activation of cell migration through Rac signaling (Chandrasekar et al., 2003; van Leeuwen et al., 2003 Kawauchi et al., 2003) and p38MAPK (Rousseau et al., 1997; Cara et al., 2001; Ishizuka et al., 2001; Kimura et al., 2003; Pichon et al., 2004) , have also been reported to be involved in cell migration. Consistent with these reports, our results indicate that activation of PI3K is required for the induction of glioma cell migration as well as for the activation of p38MAPK and JNK in response to LPA. However, Rac1 signaling is not enough to account for LPA-induced migration via Figure 5e ). The involvement of RhoA in the transduction of PI3K signaling to p38MAPK in glioma cell migration was ruled out by using Y27632, which had no effect on migration. Thus, in glioma cells, other Rholike G-proteins, such as Cdc42, might be involved in LPA-induced p38MAPK activation, hence cell migration. In fact, our results showed that Cdc42 might be essential for p38MAPK activation and migration induced by LPA (Figures 5e and 6d) . This hypothesis was supported by very recent studies showing that Cdc42 could also be important for p38MAPK-dependent T-cell chemotaxis (Shi et al., 2003) and the VEGFinduced formation of stress fibers in endothelial cells (Lamalice et al., 2004) . In prostate carcinoma cells (Edlund et al., 2002) , Cdc42 as well as RhoA could participate in not only transforming growth factor-binduced formation of stress fibers but also in membrane ruffling. It has been shown that p38MAPK, MAPKKAPKs and hsp25/27 might be involved in polymerization of actin (Ishizuka et al., 2001) . Recent finding has also shown that JNK phosphorylates paxillin, and suggested that phosphorylation of actin-associated adaptor proteins for focal adhesion is a possible mechanism through which JNK affects the organization of actin cytoskeleton and the migration of epithelial cells . However, it is still unclear as to how MAPKs participate in the regulation of cytoskeleton in cell migration, and it is important to further elucidate molecular mechanisms by which MAPKs regulate cytoskeleton downstream of Rho-like G-proteins.
In glioma cells, although LPA stimulated ERK activation, the migration was not affected by treatment of cells with the MEK inhibitors. These data are consistent with the previous observation of Bian et al. (2004) and suggest that the MEK/ERK pathway does not play a significant role in LPA-stimulated glioma cell migration. This information is of interest given the recent study showing that ERK activation is essential for LPA-induced pancreatic cancer cell migration (Stahle et al., 2003) . In addition, the migratory response to EGF seems to depend on cell type. In fact, C6 cells did not respond to EGF, but CGNH-89 cells did (Figure 4f ). Nevertheless, LPA-induced migration neither in C6 cells nor in CGNH-89 cells was affected by the inhibitor for EGF receptor kinase, although EGF receptors have been implicated in transducing LPA action on migration in some cancer cells (Gschwind et al., 2002; Schafer et al., 2004) .
In glioma cells, we found that PDGF and EGF as well as LPA stimulate cell migration (Figures 4 and 5) . To check which signaling mechanisms are involved in the regulation of PDGF-or EGF-induced migration, we treated cells with different inhibitors. Wortmannin and SB203580 significantly decreased migratory response to PDGF (Figure 5b and g ), but SP600125 or Y27632 had no such effect. We obtained a slightly different result on the EGF action, which was sensitive to SB203580 and Y27632, but not to wortmannin or SP600125 (data not shown). In contrast, as shown in Figure 5a -c, we defined that the LPA action was sensitive to wortmannin, SP600125 and SB203580. Treatment of cells with SP600125 (30 mM) completely abolished the LPA-induced activation of JNK but not ERK, while treatment of cells with PD98059 (10 mM) significantly diminished the LPA-induced activation of ERK but not JNK (Figure 7a ). In addition, treatment of cells with SB203580 (1 mM) completely abolished the LPA-induced p38MAPK activation, but the treatment with SB203580 did not influence the LPA-induced JNK activation (data not shown). The concentration of wortmannin, SP600125 and SB203580 used was sufficient to decrease the migratory response to growth factors and LPA in C6 or GNS-3314 cells. Moreover, the mechanism of S1P-induced migration in rat astrocytes resembled that of LPA in C6 cells, except that S1P action in astrocytes was suppressed by Y27632 (data not shown). Thus, JNK and p38MAPK pathways in cell migration seem to be characteristic not only for transformed glial cells but also for normal ones.
For invasion, the proteolysis of extracellular matrix proteins is an important step in addition to regulation for cell migration. In the present study, we demonstrated that LPA is a strong factor for stimulation of glioma cell migration and invasion in vitro (Figures 5 and 8) . The mechanisms involved in LPA-induced cell invasion are similar to those in cell migration. In fact, our results showed that PI3K might be essential for LPA action on migration and invasion (Figures 5a, b and 8c) . We suppose that both p38MAPK and JNK pathways may equally contribute to LPA-induced cell migration, since the effect of SB203580 and SP600125 was additive (Figure 5c ). In the case of invasion, however, SP600125 almost completely inhibited the invasive response to LPA, and therefore, JNK might be essential for LPAinduced invasion. Effect of JNK inhibitor on JNKregulated signaling pathway in migration showed a slight difference from that in invasion, which is possibly due to the involvement of JNK in the activation of matrix metalloproteinases required for invasion of glioma cells. This hypothesis is supported by a recent study showing that JNK could participate in Racdependent cancer cell invasion and be coupled to matrix metalloproteinase expression or activation (Hsia et al., 2003) .
In this study, we demonstrated that lysophospholipids, particularly LPA and S1P, have opposite effects on cell movement depending on the difference in receptor expression in normal and transformed cells. LPA, through LPA 1 receptor, stimulated glioma cell migration, while S1P, through S1P 2 receptor, negatively regulated the LPA action. LPA 1 -receptor-mediated migration has also been shown in the glioblastoma cell lines SF295 and SF539 (Hama et al., 2004) . Previously, we reported that brain is one tissue in which S1P is abundantly present . From these observations, we can hypothesize that S1P may have a certain role in brain tumorigenesis. Thus, S1P 2 receptor agonists, in addition to LPA 1 receptor antagonists, could be used as new tools of treatment, although S1P does not always exert inhibitory action on migration in glioblastoma cells (Van Brocklyn et al., 2003) . The LPA 1 receptor antagonist Ki16425, used in the present study, is one of the potential agents for such a purpose. The hallmark of malignant astrocytic tumors is their ability to infiltrate surrounding normal brain tissue. This phenotype makes complete surgical resection difficult and focal therapy ineffective. Thus, understanding the mechanisms of astrocytic tumor cell migration and invasion in the brain is essential for the development of new strategies to control this malignancy.
Materials and methods
Materials
LPA and S1P were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA); fatty acid-free BSA and U0126 were from Calbiochem-Novabiochem Co. (San Diego, CA, USA); DGPP 8:0 was from Avanti Polar Lipids Inc. (Alabaster, AL, USA); PTX was from List Biological Laboratories Inc. (Campbell, CA, USA); EGF was from Sigma; AG1478 and SP600125 were from BIOMOL Research Laboratories Inc. (Plymouth Meeting, PA, USA); PDGF-BB was from Pepro Tech House (London, England). Ki16425 was provided by Kirin Brewery Co. (Takasaki, Japan) and VPC12249 was a gift from Professor Kevin R Lynch of University of Virginia School of Medicine (Charlottesville, VA, USA). Human S1P 2 cDNA (1-431) was provided by Professor Yoh Takuwa of Kanazawa University Graduate School of Medicine (Kanazawa, Japan). The sources of all other reagents were the same as described previously Malchinkhuu et al., 2003) .
Cell culture (details are provided in the supplement) Rat C6 glioma and human 1321N1 astrocytoma cells were grown in DMEM supplemented with 10% FBS. S1P-receptor (S1P 1 or S1P 2 )-transfected C6 cells were maintained in the same medium with 100 mg/ml G418 as described in Sato et al. (2000) . GNS-3314 cells and CGNH-89 (Ishiuchi et al., 2002) , Regulation of glioma migration by lysophospholipids E Malchinkhuu et al established from human glioblastoma surgical specimens, were grown in MEM containing 10% FBS. Preparation of type-I rat astrocytes from 1-to 2-day-old Wistar rat was carried out as described in Sato et al. (1999a) .
Construction of adenoviral vector and infection of recombinant adenovirus (details are provided in the supplement)
The adenovirus carrying dominant-negative form of rat p38MAPK (p38-DN) or human Cdc42 (N17TCdc42) was constructed according to Raingeaud et al. (1995) and Edlund et al. (2002) . The recombinant adenovirus for JIP1-JBD was constructed as described previously (Maruyama et al., 2002) . A dominant-negative form of human Rac1 (T17NRac1) from Upstate (Charlottesville, VA, USA) was used for recombinant adenovirus construction.
Transfection of siRNA
When the glioblastoma cells reached approximately 75-80% confluency, the amount (total 100 nM) of LPA 1 -specific 21-nucleotide siRNAs, LPA 1 -102, -228 and -945, and nonsilencing (NS) RNA were transfected using an RNAiFect reagent (Qiagen KK, Tokyo, Japan) as described previously (Yamada et al., 2004) . For introduction of S1P 2 -specific siRNAs (M-003952-00 from Dharmacon Inc., Lafayette, CO, USA), the cells were treated with 50 nM S1P 2 -specific siRNA according to the manufacturer's instructions. After 48 h transfection, the receptor mRNA level was measured using real-time TaqMan technology, and a cell migration assay was performed 24 h after serum starvation.
Cell migration assay
The cell migration was quantified using a blind Boyden chamber apparatus (Neuro Probe Inc., Gaithersburg, MD, USA) as described previously (Kon et al., 1999) . Briefly, the lower chambers were filled with starvation medium containing the indicated concentrations of test agents, and subsequently, covered with 8-mm pores (Neuro Probe) membrane filters coated with type I collagen. The cells were trypsinized, and washed once with DMEM containing 0.1% BSA. Resuspended cells, after being incubated for 20 min without or with LPA receptor antagonists, and for 30 min with or without different inhibitors at 371C, were loaded into the upper chamber. Migration was allowed to proceed for 4 h at 371C under a humidified air/CO 2 (19 : 1) atmosphere. Cells that had migrated to the lower surface were counted in four microscopic fields at Â 400 magnification.
Matrigel invasion assay
For cell invasion activity assay, a growth factor-reduced Matrigel invasion chamber (BD Biosciences, San Jose, CA, USA) was used according to the manufacturer's instructions. The procedures were described previously, except that the incubation time was 20 h (Yamada et al., 2004) .
Northern blot analysis (details are provided in the supplement) Total RNA isolates were prepared according to the manufacturer's instructions for TRI Reagent (Sigma-Aldrich, St Louis, MO, USA). For detection of S1P and LPA receptors, Northern blot analysis was performed with cDNA probes for S1P and LPA receptors (Sato et al., 1999b; Malchinkhuu et al., 2003; Ohta et al., 2003) . For detection of S1P 2 mRNA, a 431-bp probe derived from the coding region of the human S1P 2 was used.
Quantitative RT-PCR using real-time TaqMan technology (details are provided in the supplement) DNase I-treated RNA (5 mg) was subjected to the quantitative RT-PCR using real-time TaqMan technology (Yamada et al., 2004) . The human LPA 1 -, LPA 2 -, LPA 3 -, S1P 1 -, S1P 2 -, S1P 3 -and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific probes were obtained from Assay-onDemand products: Hs00173500 for LPA 1 , Hs00173704 for LPA 2 , Hs00173857 for LPA 3 , Hs00173499 for S1P 1 , Hs00244677 for S1P 2 , Hs00245464 for S1P 3 and Hs99999905 for GAPDH (Applied Biosystems, Foster City, CA, USA).
Estimation of ERK and JNK activation by Western blot analysis (details are provided in the supplement) Anti-phosphorylated ERK (p-p44 and p-p42) antibodies and anti-phosphorylated JNK (p-p54 and p-p46) antibodies were used. These antibodies, together with anti-JNK (p54 and p46) antibodies that recognize the kinases independent of their phosphorylation state, were obtained from Cell Signaling Technology (Beverly, MA, USA). The cells were serum starved for more than 18 h before incubation with the HEPES-buffered medium containing various test substances for the indicated times at 371C. Cytosol fractions were prepared and subjected to the Western blot analysis (Sato et al., 1999b) .
Evaluation of p38MAPK activity
The cells were treated in a way similar to that shown in the ERK and JNK assay, except that the glioma cells were stimulated for 10 min. For measurement of p38MAPK activity, the phosphorylated p38MAPK in the lysate was immunoprecipitated and its activity was evaluated by its ability to phosphorylate the activating transcription factor-2 fusion protein according to the manufacturer's instructions for p38MAPK assay kit from Cell Signaling Technology (Beverly, MA, USA). The expression of total p38MAPK proteins was also examined with p38MAPK antibodies obtained from Cell Signaling Technology.
Data presentation
All experiments were performed in duplicate or triplicate. The results of multiple observations are presented as the mean7 s.e.m. or as representative results from more than three different batches of cells, unless otherwise stated. Statistical significance was assessed by the Student's t-test; values were considered significant at Po0.05.
Abbreviations LPA, 1-oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid; S1P, sphingosine-1-phosphate; PI3K, phosphatidylinositol 3-kinase; MAP kinase, mitogen-activated protein kinase; p38MAPK, p38MAP kinase; p38-DN, dominant-negative mutant for p38MAPK; JNK, c-Jun terminal kinase; JIP1-JBD, JNK-binding domain of JNK-interacting protein-1; ERK, extracellular signal-regulated kinase; MEK, ERK kinase; T17NRac1, dominant-negative mutant for Rac1; T17NCdc42, dominant-negative mutant for Cdc42; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; DGPP 8:0, dioctylglycerol pyrophosphate; G-protein, GTP-binding regulatory protein; PTX, pertussis toxin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein.
